

Attorney Ref. 04676.105047

1641

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: **Russell Medford, et al.**

Serial No.: **09/436,892**

Examiner: **Gabel, G.**

Filed: **November 09, 1999**

Art Unit: **1641**

For: **METHODS AND COMPOSITIONS TO LOWER PLASMA CHOLESTEROL LEVELS**

Assistant Commissioner for Patents
Washington, DC 20231

TECH CENTER 1600/2900

AUG 23 2001

RECEIVED

#9/B
Angela
8/25/01

CORRECTED AMENDMENT AND RESPONSE TO OFFICE ACTION

Sir:


In response to the communication mailed July 17, 2001, Applicants have attached a corrected marked-up version of the claim amendments as requested by the Examiner. Although no additional fees are believed by the Applicants to be due, the Commissioner is hereby authorized to charge any requisite fees to Deposit Account No. 11-0980.

Information Disclosure Statement

The concise statement of relevancy for the French patent documents listed on the Information Disclosure Statement at AQ-AV was provided in the specification as originally filed at page 7, lines 28-33 (MPEP § 609 (A(3))). A full translation of the most representative French patent is enclosed for the Examiner's further consideration. The Examiner's attention is also directed to the fact that U.S. Patent No. 5,262,439 (cited on the February 28, 2000 Information Disclosure Statement) is commonly owned by AtheroGenics, Inc. with the present application.

CERTIFICATE OF MAILING (37 CFR 1.8a)

I hereby certify that this Amendment and Response to Office Action, along with any paper referred to as being attached or enclosed, is being deposited with the United States Postal Service on the date shown below with sufficient postage as first-class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.



Joseph M. Bennett-Paris, Ph.D.

August 17, 2001
Date